iShares Nasdaq Biotechnology (IBB) Poised to Open Up Over 2%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
Go back to iShares Nasdaq Biotechnology (IBB) Poised to Open Up Over 2%
March 23, 2015 6:54 AM EDT
Baird analyst Brian Skorney weighed in on Gilead Sciences (NASDAQ: GILD) following Harvoni/Sovaldi labeling changes. The firm reiterated an Outperform rating and price target of $126, saying the changes are not meaningful.
Skorney commented, "No change to view following Harvoni/Sovaldi labeling... More
March 20, 2015 10:28 AM EDT
Leerink Partners analyst Joseph Schwartz reiterated an Outperform rating and lifted his price target on Biogen (NASDAQ: BIIB) to $532.00 (from $475.00)
Schwartz said, "This morning at the ADPD15 meeting, BIIB reported better than expected results from BIIB037s Ph. Ib trial on both... More
March 20, 2015 10:28 AM EDT
iShares Nasdaq Biotechnology (NASDAQ: IBB) Makes Green to Red Reversal
...
More
March 20, 2015 9:39 AM EDT
Citi reiterated a Buy rating and boosted its price target on Biogen (NASDAQ: BIIB) to $512.00 (from $410.00) following solid potency data on BIIB037, although main question in dose/safety.
"The only question is safety as 32% of patients on the high does... More
